Journal of Biological Chemistry
Volume 287, Issue 50, 7 December 2012, Pages 41651-41666
Journal home page for Journal of Biological Chemistry

Lipids
Novel Keto-phospholipids Are Generated by Monocytes and Macrophages, Detected in Cystic Fibrosis, and Activate Peroxisome Proliferator-activated Receptor-γ*

https://doi.org/10.1074/jbc.M112.405407Get rights and content
Under a Creative Commons license
open access

12/15-Lipoxygenases (LOXs) in monocytes and macrophages generate novel phospholipid-esterified eicosanoids. Here, we report the generation of two additional families of related lipids comprising 15-ketoeicosatetraenoic acid (KETE) attached to four phosphatidylethanolamines (PEs). The lipids are generated basally by 15-LOX in IL-4-stimulated monocytes, are elevated on calcium mobilization, and are detected at increased levels in bronchoalveolar lavage fluid from cystic fibrosis patients (3.6 ng/ml of lavage). Murine peritoneal macrophages generate 12-KETE-PEs, which are absent in 12/15-LOX-deficient mice. Inhibition of 15-prostaglandin dehydrogenase prevents their formation from exogenous 15-hydroxyeicosatetraenoic acid-PE in human monocytes. Both human and murine cells also generated analogous hydroperoxyeicosatetraenoic acid-PEs. The electrophilic reactivity of KETE-PEs is shown by their Michael addition to glutathione and cysteine. Lastly, both 15-hydroxyeicosatetraenoic acid-PE and 15-KETE-PE activated peroxisome proliferator-activated receptor-γ reporter activity in macrophages in a dose-dependent manner. In summary, we demonstrate novel peroxisome proliferator-activated receptor-γ-activating oxidized phospholipids generated enzymatically by LOX and 15-prostaglandin dehydrogenase in primary monocytic cells and in a human Th2-related lung disease. The lipids are a new family of bioactive mediators from the 12/15-LOX pathway that may contribute to its known anti-inflammatory actions in vivo.

Eicosanoid
Innate Immunity
Lipoxygenase Pathway
Macrophages
Mass Spectrometry (MS)
Monocytes
Phospholipid

Cited by (0)

*

This work was supported, in whole or in part, by National Institutes of Health Grants HL068878 and HL89544 (to Y. E. C. and L. V.); R01-HL058115, R01-HL64937, P30-DK072506, and P01-HL103455 (to B. A.F.); and R01-AT006822-01 (to F. J. S.). This work was also supported by the Wellcome Trust (to V. B. O., C. M. L, N. P., Y. G. D., and V. H.), a European Union Marie Curie fellowship (to C. P. T.), American Heart Association Grant 10SDG4150085 (to L. V.), the American Diabetes Association (to F. J. S.), the Academy of Finland and the Sigrid Juselius Foundation (to A. L. L. and E. K.), and American Diabetes Association Junior Faculty Award 7-08-JF 52 (to F. J. S.). B.A.F. acknowledges financial interest in Complexa, Inc. and Nitromega, Inc.